自动非共面VMAT剂量递增SBRT再程放疗复发头颈癌的II期研究
1年局部控制率为83.8%(95%CI 62.4-93.6%),1年≥3级治疗相关毒性为17.4%,均优于历史对照。
要点
- 自动非共面VMAT计划可为全部患者实现更高靶区剂量且不增加危及器官剂量。
- 1年局部控制率83.8%,高于传统VMAT SBRT历史对照的60%。
- 1年≥3级毒性17.4%,未高于历史对照的20%。
核心结论
- 自动非共面VMAT实现的剂量递增SBRT再程放疗,其1年局部控制率优于历史对照,且≥3级毒性未升高。
研究设计与样本
- 患者同时制定传统VMAT(≤40 Gy)与自动非共面VMAT(≤55 Gy)计划,均分5次隔日照射,若非共面计划能在不增加危及器官剂量前提下给予更高靶区剂量则选用。
主要发现
- 全部患者均选用非共面VMAT计划而非传统VMAT计划。
- 中位随访18.1个月(四分位距10.9-36.3)。
- 1年局部控制率为83.8%(95%CI 62.4-93.6%)。
- 1年≥3级治疗相关毒性为17.4%。
关键数值与推荐
- 主要终点为1年局部控制率(对比传统VMAT SBRT历史率60%)和1年≥3级治疗相关毒性(对比历史率20%)。
- 局部控制采用Kaplan-Meier法估计,毒性按CTCAE v5.0分级。
- 再程放疗SBRT处方剂量:传统VMAT≤40 Gy、自动非共面VMAT≤55 Gy,均分5次隔日照射。
临床怎么用
- 对既往接受过头颈部放疗、病灶直径<5 cm的复发患者,可考虑采用自动非共面VMAT制定剂量递增SBRT再程放疗计划。
- 计划选择时优先选用能在不增加危及器官剂量前提下给予更高靶区剂量的非共面VMAT方案。
局限性
- 单臂设计,主要终点与历史对照比较而非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Re-irradiation for recurrent head and neck cancer is associated with poor local control and significant treatment-related toxicity. We hypothesized that automated non-coplanar volumetric modulated arc therapy (VMAT) can deliver more conformal, dose-escalated stereotactic body radiotherapy (SBRT) plans than conventional VMAT, which may improve local control without increasing toxicity. MATERIALS AND METHODS: This was a single-arm, phase II trial that enrolled patients with histologically-confirmed, recurrent head and neck cancer (diameter < 5 cm) with prior head and neck radiotherapy. Patients were planned for treatment using both conventional VMAT (≤40 Gy) and automated non-coplanar VMAT (≤55 Gy) in 5 every-other-day fractions. Non-coplanar VMAT plans were selected if they could deliver higher planning target volume doses without higher organ-at-risk doses. The primary endpoints were one-year local control (compared to the historical rate of 60 % with SBRT using conventional VMAT) and one-year grade ≥ 3 treatment-related toxicity (compared to the historical rate of 20 %). Local control was estimated via Kaplan-Meier method. Toxicities were graded using Common Terminology Criteria for Adverse Events, v5.0. RESULTS: Twenty-nine patients were enrolled between February 2020-November 2023. Median follow-up was 18.1 months (interquartile range, 10.9-36.3). Non-coplanar VMAT plans were selected over conventional VMAT for all patients. One-year local control was 83.8 % (95 % confidence interval [CI], 62.4-93.6 %). One-year grade ≥ 3 toxicity was 17.4 %. CONCLUSION: Automated non-coplanar VMAT achieved superior one-year local control compared to the historical local control rate without higher grade ≥ 3 toxicity. This represents one of the highest local control rates reported in a prospective trial of head and neck re-irradiation and a new approach to head and neck SBRT.
引用
- Nikitas J, Ma TM, Cook K, et al. Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy. Radiother Oncol. 2025. PMID: 41242408. doi:10.1016/j.radonc.2025.111283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。